Evidence map›Paper›PMID 29305710›Full record

ArticleJournal of cancer research and clinical oncology2018

Ecto-5'-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line.

Fabrícia Dietrich, Fabrício Figueiró, Eduardo Cremonese Filippi-Chiela, Angélica Regina Cappellari, Liliana Rockenbach, Alain Tremblay, Patrícia Boni de Paula, Rafael Roesler, Aroldo Braga Filho, Jean Sévigny and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Review
  3. Adenosinergic Signalling in Cervical Cancer Microenvironment.Expert reviews in molecular medicine · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Targeting CD73 to augment cancer immunotherapy.Current opinion in pharmacology · 2020
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Fabrícia DietrichPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, CEP 90035-003, Brazil.ORCID http://orcid.org/0000-0002-6458-2359
Fabrício FigueiróPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, CEP 90035-003, Brazil.
Eduardo Cremonese Filippi-ChielaPrograma de Pós-Graduação Ciências em Gastroenterologia e Hepatologia, Faculdade de Medicina, UFRGS, Porto Alegre, RS, CEP 90035-003, Brazil.
Angélica Regina CappellariLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde, PUCRS, Porto Alegre, RS, CEP 90619-900, Brazil.
Liliana RockenbachPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, CEP 90035-003, Brazil.
Alain TremblayCentre de Recherche du CHU de Québec, Université Laval, Quebec, QC, G1V 4G2, Canada.
Patrícia Boni de PaulaDepartamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, CEP 90035-003, Brazil.
Rafael RoeslerLaboratório de Câncer e Neurobiologia, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, CEP 90035-003, Brazil.
Aroldo Braga FilhoServiço de Radioterapia, Hospital São Lucas da PUCRS, Porto Alegre, RS, CEP 90619-900, Brazil.
Jean SévignyCentre de Recherche du CHU de Québec, Université Laval, Quebec, QC, G1V 4G2, Canada.
Fernanda Bueno MorroneLaboratório de Farmacologia Aplicada, Escola de Ciências da Saúde, PUCRS, Porto Alegre, RS, CEP 90619-900, Brazil.
Ana Maria Oliveira BattastiniPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, CEP 90035-003, Brazil. abattastini@gmail.com.
Universidade Federal do Rio Grande do Sul · BRPontifícia Universidade Católica do Rio Grande do Sul · BRUniversité Laval · CAHospital São Lucas da PUCRS · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 303264/2013-6Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul 16/2551-0000473-0
6 · The paper itself

Abstract

purposeTrimodal therapy is a reasonable bladder-preserving option to radical cystectomy. However, many tumors are radioresistive. In this sense, the identification of new prognostic and predictive biomarkers that allow the selection of patients with better responses to radiation therapy would improve outcomes. With the aim of using ecto-5'-nucleotidase/CD73 as a predictive biomarker, the role of this enzyme in the context of radiotherapy in T24 human bladder cancer cell line was investigated.

methodsT24 cell line was exposure to a single dose of radiation (4 Gray) and trypan blue assay (pharmacological assays of viability/cumulative population doubling), flow cytometry (cell cycle/cell death/active caspase-3/ecto-5'-nucleotidase/CD73 protein staining), DAPI staining (nuclear morphometric assay), RT-PCR and real-time PCR, malachite green method (ectonucleotidase enzymatic assay), and HPLC (analysis of AMP metabolism) were carried out. T24 cell line in which ecto-5'-nucleotidase/CD73 has been completely silenced (5'KO) was also used.

resultsThe exposure of T24 cell line to a single dose (4 Gray) of radiation-induced cell death and triggered a transitory increase in ecto-5'-nucleotidase/CD73 expression, increased ectonucleotidase activity, and led to adenosine and inosine accumulation in the extracellular medium. Pharmacological inhibition or knocking out ecto-5'-nucleotidase/CD73 rescued cells' proliferative capacity, reducing their sensitivity to radiation.

conclusionOur findings show that the induction of ecto-5'-nucleotidase/CD73 by radiation contributes to the radiosensitivity of T24 cell line.

Indexed as

5'-NucleotidaseCell Line, TumorCell ProliferationGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticGene Knockdown TechniquesGPI-Linked ProteinsHumansRadiation DosageRadiation ToleranceUrinary Bladder Neoplasms5'-NucleotidaseGPI-Linked ProteinsNT5E protein, humanBladder carcinomaEctonucleotidasePurinergic signalingRadiotherapyT24 cell line

Identifiers

PMID29305710
PMCPMC11813468
OpenAlexW2782034097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.